ERYTECH
announces its participation
at
investor conferences
in April
Lyon, France),
and Cambridge, MA (US)
the 28th
March
202
2
–
ERYTECH
Pharma (Euronext: ERYP
; Nasdaq: ERYP), company
clinical-stage biopharmaceutical that develops innovative therapies by encapsulating drugs in red blood cells
(GR)
,
announcement
today
that his
General manager
,
Gil Beyen
and its Chief Financial and Operations Officer
,
Eric Soyer will participate
at the following conferences during the month of April and offers investors individual meetings
.
Investor Access
Event
Event link
Date: April 4 and 5, 2022
Location: Paris (France)
Participant: Eric SOYER (Financial and Operations Director)
If you would like to arrange a one-on-one meeting, please contact the conference representative.
Kempen
14
th
Life Sciences Conference
Event link
Date: April 21, 2022
Location: Amsterdam (Netherlands)
Participants: Gil BEYEN (General Manager) and Eric SOYER (Financial and Operations Director)
If you would like to arrange a one-on-one meeting, please contact the conference representative.
About ERYTECH and eryaspase
(GRASPA®)
www.erytech.com
Founded in Lyon in 2004, ERYTECH is a clinical-stage biopharmaceutical company that develops innovative therapies based on red blood cells to fight against cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, an innovative technology for encapsulating drugs in red blood cells, ERYTECH is developing a portfolio of product candidates targeting markets with significant unmet medical needs. ERYTECH mainly focuses on the development of products targeting metabolic disturbances in cancer cells, in order to deprive them of the amino acids necessary for their growth and survival.
The Company’s lead product, eryaspase (GRASPA®), consisting of L-asparaginase encapsulated in red blood cells from donors, addresses the altered asparagine and glutamine metabolism of cancer cells. The proof of concept of eryaspase as a metabolic agent against cancer has been established in different trials on acute lymphoblastic leukemia (ALL) and pancreatic cancer. A phase 2 investigator-sponsored study (IST) evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently showed positive results, based on which the Company intends to file for approval in the United States and potentially in other territories. A Phase 2 study in metastatic triple-negative breast cancer and an investigator-sponsored Phase 1 clinical study in the first-line treatment of advanced pancreatic cancer are ongoing.
Eryaspase has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to pegylated asparaginase and for the treatment of cancer of the advanced pancreas. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of ALL and pancreatic cancer.
ERYTECH produces its drug candidates for the treatment of patients in Europe at its GMP-compliant production site in Lyon, France, and for patients in the United States at its GMP-compliant production site in New Jersey, USA. Eryaspase is not approved in any country.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC
Mid
& Small, CAC All
Tradable
,
EnterNext
PEA-PME 150 and Next Biotech.
CONTACTS
|
ERYTECH Eric Soyer Chief Financial Officer and Director of Operations |
NewCap Mathilde Bohin/Louis-Victor Delouvrier Investor Relations Nicolas Merigeau Media Relations |
+33 (0)4 78 74 44 38 | +33 (0)1 44 71 94 94 |
Attachment
220328_ERYTECH_CP_APR 2022 Conferences Invest_FR_vf-2